The TRIPS Agreement plays a significant role in the availability and affordability of cancer treatments. By setting standards for patent protection, TRIPS ensures that new pharmaceutical innovations are protected, allowing companies to recoup research and development costs. However, this can lead to high prices for patented cancer drugs, affecting accessibility for patients in low- and middle-income countries.
